Genetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant

Guest: Sergio Baranzini, PhD <br> <article data-scroll-anchor="false" data-testid="conversation-turn-2" data-turn="assistant" data-turn-id="request-WEB:06339a64-6051-447a-b4e9-e04cdbfe923e-0" dir="auto" tabindex="-1"> <div> <div tabindex="-1"> <div> <div data-message-author-role="assistant" data-message-id="18206383-12da-4894-8e42-bc64a2611dde" data-message-model-slug="gpt-4o" dir="auto"> <div> <div> <p data-end="1273" data-is-last-node="" data-is-only-node="" data-start="331">In a landmark study involving over 10,000 patients, the International MS Genetics Consortium (IMSGC) has identified the first genetic variant associated with disease severity in multiple sclerosis (MS). Dr. Sergio Baranzini, a Distinguished Professor of Neurology at the University of California, San Francisco Weill Institute for Neurosciences, explains what's next in researching this variant and working towards effective treatments. Dr. Baranzini also spoke on this topic at the 2025 Congress of the E...